Navigation Links
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
Date:4/22/2008

nt funding.

"The SBIR grant for sepsis, with its $3 million budget, will allow us to conduct the study with enough patients to provide an answer regarding talactoferrin's activity in the clinical setting," said Robert Lodato, M.D., Associate Professor of Medicine, University of Texas Health Science Center, and Medical Monitor for the study.

About the Phase 2 Study

The double-blind, placebo-controlled Phase 2 study of talactoferrin will enroll 190 patients who have a diagnosis of sepsis with at least one organ dysfunction due to sepsis. Patients will receive standard therapy (including, at the discretion of the primary physician, drotrecogin alfa activated, marketed as Xigris(R)(1), and will be randomly assigned (1:1) to receive either talactoferrin (1.5 g) or placebo three times a day for up to 28 days or until discharge from the intensive care unit (ICU), whichever occurs first. The primary efficacy endpoint of the trial is 28-day all-cause mortality. Secondary endpoints include number of ICU days, shock-free days, incidence and severity of organ failure/dysfunction and circulating levels of pro- inflammatory cytokines. Safety will be monitored and patients will be followed for survival at three and six months post-randomization.

About Sepsis

Sepsis is a clinical syndrome consisting of known or suspected infection and associated inflammatory response. Severe sepsis is defined as the presence of sepsis with dysfunction of one or more organs. The incidence of sepsis in the United States is estimated to be approximately 750,000 cases per year, with an annual increase of approximately 1.5%, and estimated mortality due to sepsis of 210,000 deaths each year. According to the Centers for Disease Control and Prevention, sepsis is among the top 10 leading causes of death in the United States.

Treatment for sepsis consists of eradicating the underlying infection and providing supportive care for any associated organ dysfunction. In N
'/>"/>

SOURCE Agennix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
6. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
11. Metabolex Initiates Phase 1 Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
(Date:10/17/2014)... , Oct. 17, 2014 Research ... "Research and Development Prospect of China Dialysis ... Based on the 2013 version, this ... policies about dialysis industry and the relevant effect ... about dialysis industry segmentations. Moreover, it analyzes Chinese ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... 31st European Cystic Fibrosis Conference -, SOUTH ... /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) today announced promising ... fibrosis (CF). Results from an Israeli Phase 2a,extension ... in adult,patients with nonsense-mutation-mediated CF demonstrated statistically,significant improvements ...
... Data from Positive Phase 2a Trial, WALTHAM, ... ) today announced that based on feedback from ... initiate a Phase 2b clinical,trial of RG2417, an ... later this year. This will be a multi-center, ...
Cached Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... 2008) The Virginia Commonwealth University School of Medicine ... from the National Institutes of Healths National Institute on ... syndrome, a disorder of the endocrine system that affects ... syndrome, or PCOS, causes hormonal imbalances leading to irregular ...
... LAKE CITY, May 12 Dynatronics,Corporation (Nasdaq: ... quarter,ended March 31, 2008 on Wednesday, May 14, ... for investors later that,day at 2:30 p.m. ET ... nine month,periods. Those interested in participating should call ...
... to expand oral health care services; awards two significant oral health ... ... As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, five-year,initiative to ... to announce a request for proposals in the oral,health care field. The ...
... http://www.cryocath.com Toronto Stock Exchange Symbol: CYT, MONTREAL, ... in cryotherapy products to treat cardiac,arrhythmias, today announced financial ... Selected Second Quarter Financial and Operational Highlights:, ... to $10.2 million or a 37.6% ...
... MELVILLE, N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... health services, announced today that it is scheduled to,present ... 21, 2008 at the 2008,Citi Investment Research Global Health ... be available to the public via a live audio ...
... Low IQ more likely the younger a child is at diagnosis, ... about 5 percent of people with multiple sclerosis are diagnosed when ... cognitive function, causing memory and attention problems, and possibly low IQ ... time of diagnosis, the more likely he or she is to ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3
Schlesinger Laminectomie Rongeur, golden springs. 15 cm - 6, with narrow footplate, large handle, 40 down-cutting, jaws 3 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch...
... Osteopal V is a low viscosity ... use in vertebroplasty. The bone cement is ... stabilization purposes. Osteopal V is used for ... concentration of zirconium dioxide is included in ...
Medicine Products: